Lab Reference Library / Fecal Calprotectin
Gut & Immune
Fecal Calprotectin
Fecal Calprotectin · Stool CalprotectinReference range, optimal levels, and why fecal calprotectin is the most sensitive and specific non-invasive biomarker for intestinal inflammation, how it distinguishes inflammatory bowel disease from irritable bowel syndrome, and why it is essential for IBD monitoring and relapse detection.
Intestinal InflammationIBD Monitoring
Standard RangeBelow 50 mcg/g
FM OptimalBelow 50 mcg/g
Borderline50 to 200 mcg/g
Unitsmcg/g stool
← Back to Lab Reference Library
Category: Gut & Immune | Also known as: Stool Calprotectin, FC, Intestinal Inflammation Marker
1. What This Test Measures
Fecal calprotectin measures the concentration of calprotectin in stool, expressed in micrograms per gram of stool. Calprotectin is a calcium and zinc-binding protein that constitutes approximately 60% of the total cytoplasmic protein in neutrophils. When the intestinal mucosa is inflamed, neutrophils migrate from the bloodstream into the intestinal lumen and release calprotectin as they disintegrate in the gut. Fecal calprotectin levels therefore correlate directly and proportionally with the degree of neutrophilic mucosal inflammation: the more severe the intestinal inflammation, the more neutrophils migrate, and the higher the calprotectin concentration in stool.
This makes fecal calprotectin the most sensitive non-invasive biomarker for intestinal mucosal inflammation currently available, with sensitivity above 90% for detecting active IBD and sensitivity and specificity both above 85% for distinguishing IBD from irritable bowel syndrome. Unlike serum inflammatory markers such as CRP and ESR, fecal calprotectin is anatomically specific to intestinal inflammation, not affected by systemic inflammation elsewhere in the body, making it far more useful for gut-specific assessment.
2. Reference Ranges and Clinical Thresholds
| Fecal Calprotectin | Interpretation |
|---|---|
| Below 50 mcg/g | Normal: no significant intestinal mucosal inflammation; IBS-consistent pattern |
| 50 to 100 mcg/g | Borderline: mild elevation; clinical correlation required; repeat in 4 to 6 weeks |
| 100 to 200 mcg/g | Mildly elevated: meaningful mucosal inflammation; investigate for organic pathology; colonoscopy consideration |
| 200 to 500 mcg/g | Elevated: significant intestinal inflammation; high probability of IBD or other organic pathology; colonoscopy indicated |
| Above 500 mcg/g | Markedly elevated: severe intestinal inflammation; active IBD flare most likely; urgent gastroenterology evaluation |
Children below 5 years of age have physiologically higher calprotectin levels (often above 50 mcg/g) and require age-specific reference ranges. NSAIDs and aspirin increase fecal calprotectin by causing gut mucosal inflammation independent of IBD, which can produce false-positive elevations. Proton pump inhibitors may also mildly elevate calprotectin. Always interpret in context of medication history and clinical presentation.
3. IBD vs IBS: The Most Important Diagnostic Use
Distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) is the primary clinical application of fecal calprotectin. IBS is a functional disorder of gut-brain interaction without mucosal inflammation; fecal calprotectin is below 50 mcg/g in the vast majority of IBS patients. IBD (Crohn's disease and ulcerative colitis) involves active mucosal neutrophilic infiltration; calprotectin is consistently elevated above 100 to 200 mcg/g during active disease and above 50 mcg/g even in remission in many patients.
Using calprotectin as a first-line screening step in patients presenting with chronic diarrhea, abdominal pain, and bloating significantly reduces the number of colonoscopies required to rule out organic disease. A calprotectin below 50 mcg/g in a patient with IBS-consistent symptoms reduces the pre-test probability of IBD sufficiently that colonoscopy can often be deferred with monitoring. A calprotectin above 200 mcg/g in this same patient population is an indication for colonoscopy regardless of symptom pattern.
4. Uses in IBD Monitoring and Mucosal Healing Assessment
- Detecting subclinical inflammation in remission: clinical remission (absence of symptoms) does not always correlate with mucosal healing; patients in symptomatic remission can have persistent mucosal inflammation (calprotectin above 100 to 200 mcg/g) that predicts future relapse; serial calprotectin monitoring identifies these patients before symptoms return
- Predicting IBD relapse: rising calprotectin levels in a patient in clinical remission are a reliable early indicator of impending relapse; a rise from below 50 to above 150 to 200 mcg/g in a patient with established IBD typically precedes clinical flare by weeks to months, allowing preemptive treatment escalation
- Monitoring treatment response: calprotectin falls proportionally with mucosal healing during effective IBD therapy; it is used to confirm that biologics, aminosalicylates, or dietary interventions are producing objective mucosal improvement rather than only symptom relief
- Post-surgical monitoring in Crohn's disease: calprotectin detects recurrent mucosal inflammation at the anastomosis site after ileocecal resection, often before endoscopic recurrence is visible
- Distinguishing active IBD from functional symptoms in known IBD patients: patients with established IBD frequently develop IBS-like functional symptoms independent of inflammation; calprotectin helps determine whether new symptoms represent a genuine flare requiring treatment change or functional overlay not requiring escalation
5. Other Causes of Elevated Fecal Calprotectin
- Infectious gastroenteritis: bacterial, viral, and parasitic intestinal infections produce significant calprotectin elevation that resolves with infection resolution; calprotectin above 200 mcg/g with acute diarrhea onset is consistent with infectious cause
- NSAID and aspirin use: NSAIDs cause direct intestinal mucosal injury and neutrophilic infiltration independent of IBD; patients on regular NSAIDs frequently have calprotectin above 50 to 100 mcg/g without organic bowel disease
- Colorectal cancer and polyps: mucosal tumors and large polyps produce local inflammatory infiltrates that elevate calprotectin; significantly elevated calprotectin in a patient above 45 without known IBD warrants colonoscopy regardless of other factors
- Celiac disease: active celiac disease produces mucosal neutrophilic inflammation in the proximal small intestine that can elevate calprotectin above 50 mcg/g; calprotectin normalizes with strict gluten elimination in responsive celiac patients
- Microscopic colitis: lymphocytic and collagenous colitis (subtypes of microscopic colitis presenting with chronic watery diarrhea) consistently elevate fecal calprotectin despite normal colonoscopic appearance, requiring mucosal biopsy for definitive diagnosis
- Food protein-induced enterocolitis (FPIES) and food sensitivity: IgE-mediated and non-IgE-mediated food reactions causing mucosal inflammation elevate calprotectin; elimination of offending foods produces calprotectin normalization
6. Related Lab Tests
ZonulinIntestinal Permeability Companion
→
Secretory IgAMucosal Immune Defense Status
→
hs-CRPSystemic Inflammation; Less Gut-Specific Than Calprotectin
→
TPO AntibodiesAutoimmune Context for Gut Inflammation
→
FerritinIBD Commonly Produces Iron Deficiency; Monitor Together
→
ALTLiver Involvement in IBD and Gut Inflammation
→
7. Clinical Perspective
Clinical Perspective
Fecal calprotectin is the test I reach for first when a patient presents with chronic GI symptoms and I need to decide how urgently to pursue invasive evaluation. A calprotectin below 40 in a patient with bloating, cramping, and altered bowel habits tells me we are very likely dealing with a functional disorder, and I can pursue a comprehensive functional medicine gut assessment without rushing the patient to colonoscopy. A calprotectin of 340 in that same patient tells me there is active mucosal inflammation that needs endoscopic characterization before I implement any gut protocol, because the treatment for active Crohn's is categorically different from the treatment for IBS with dysbiosis. The test routes the clinical decision. I also use it for monitoring my IBD patients in remission: a calprotectin trending from 45 to 180 over two consecutive quarterly checks is a patient I am going to reach out to proactively, because that trajectory historically precedes a clinical flare by 4 to 8 weeks, and catching it early produces a much better outcome than waiting for the symptoms to return.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
8. Frequently Asked Questions
What is fecal calprotectin and why is it measured?
Fecal calprotectin measures the concentration of a neutrophil protein in stool that is released in direct proportion to intestinal mucosal inflammation. It is the most sensitive non-invasive marker for gut mucosal inflammation available, capable of distinguishing inflammatory bowel disease from functional disorders like IBS with sensitivity and specificity above 85%, and is used to monitor mucosal healing in Crohn's disease and ulcerative colitis without requiring repeated colonoscopy.
What does elevated fecal calprotectin mean?
Values above 50 mcg/g indicate measurable intestinal mucosal inflammation. Borderline values of 50 to 200 mcg/g warrant clinical correlation and often repeat testing in 4 to 6 weeks. Values above 200 mcg/g indicate significant mucosal inflammation requiring investigation for IBD, colorectal cancer, infectious cause, or other organic pathology. Values above 500 mcg/g in a patient with known IBD strongly suggest an active flare requiring prompt assessment.
Can fecal calprotectin distinguish IBD from IBS?
Yes, with high accuracy. IBS is a functional disorder without mucosal inflammation; calprotectin is below 50 mcg/g in the overwhelming majority of IBS patients. IBD involves active mucosal neutrophilic infiltration; calprotectin is reliably elevated in active disease and often borderline even in remission. A negative calprotectin result substantially reduces the pre-test probability of IBD and can defer colonoscopy in patients with IBS-consistent symptom patterns.
How is fecal calprotectin used in IBD monitoring?
In established IBD, serial calprotectin testing every 3 to 6 months monitors mucosal healing during treatment and detects subclinical relapse before symptoms return. Rising calprotectin from below 50 toward above 150 to 200 mcg/g in a patient in remission typically precedes clinical flare by weeks to months, allowing preemptive treatment escalation. It also confirms whether current therapy is achieving objective mucosal healing rather than only symptomatic improvement.
Does anything falsely elevate fecal calprotectin?
Regular NSAID and aspirin use causes direct mucosal injury that elevates calprotectin independent of IBD, often above 50 to 100 mcg/g. Acute infectious gastroenteritis also elevates calprotectin dramatically. Proton pump inhibitors may mildly elevate calprotectin. Children below age 5 have physiologically higher baseline values requiring age-specific interpretation. These factors must be considered when interpreting borderline elevations in the 50 to 200 mcg/g range.
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Fecal calprotectin below 50 is not IBD. Above 200 is not IBS. That distinction changes the entire clinical pathway.
The gut panel that distinguishes functional from organic intestinal disease without colonoscopy saves time, cost, and unnecessary invasive testing. Schedule a consultation for a complete gut health evaluation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.